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Introduction {#sec1}
============

In many human cancers, including melanoma and breast cancer, tumor-associated lymphangiogenesis predicts increased metastasis and poor clinical outcome ([@bib10], [@bib44]), and overexpression of (lymph-) angiogenic factors promotes tumor lymphangiogenesis and lymph node (LN) metastasis in experimental models ([@bib26], [@bib42], [@bib43]), which has recently been shown to contribute to systemic metastasis ([@bib4], [@bib33]). Lymphangiogenesis also occurs in tumor-draining LNs. For instance, mice overexpressing vascular endothelial growth factor (VEGF)-A or VEGF-C in a model of chemically induced skin carcinogenesis showed prominently enhanced LN lymphangiogenesis, concomitant with a significant increase of LN and distant organ metastasis ([@bib17], [@bib18]). Importantly, these and other studies using experimental models of nasopharyngeal carcinoma ([@bib34]) and malignant melanoma ([@bib13], [@bib16]) have identified the onset of LN lymphatic remodeling prior to the colonization of the LN by metastatic cells. These data suggest that, even in the absence of metastatic tumor cells, tumor-associated lymphangiogenic factors can be drained from the primary tumor or released by locally activated cells to initiate changes in preparation of a pre-metastatic "lymphovascular niche" ([@bib17], [@bib28], [@bib29]). LN lymphangiogenesis has also been found in patients with malignant melanoma and human breast cancer, where the extent of lymphangiogenesis in sentinel LNs predicted an increase in the occurrence of distant LN metastases ([@bib8], [@bib32], [@bib47]).

Interestingly, accumulating evidence suggests that tumor cells can express receptors for lymphatic endothelial cell (LEC)-produced chemokines that support their migration toward lymphatic vessels and LNs, hijacking physiologic pathways for leukocyte homing ([@bib27], [@bib50]). Moreover, LN LECs have been proposed to provide a cancer stem cell niche by producing chemokines that support the survival of cancer cells with stem-like properties and high metastatic potential ([@bib20], [@bib24]). Recent findings indicate that LN LECs can directly modulate immune responses and that the lymphatic system might decisively shape the immune response to the tumor (reviewed in [@bib36]). Together, these studies indicate that LECs in the tumor and in draining LNs might play an important role in tumor progression.

Although LN lymphatic remodeling has been described in murine tumor models and human cancers, an extensive morphological and molecular characterization of this process has been lacking. In this study, we thoroughly characterized the expansion of the lymphatic network in tumor-draining LNs over time. We also performed transcriptional profiling of LN LECs isolated from two different murine tumor models and identified a transcriptional profile that is common in both models. Together, these studies provide a comprehensive portrait of the structural and molecular adaptations of LN LECs in response to tumor stimuli, and they identify pathways that may regulate these processes.

Results {#sec2}
=======

Lymphatic Network Expansion in Tumor-Draining LNs Is Mediated by LEC Sprouting and Proliferation {#sec2.1}
------------------------------------------------------------------------------------------------

We used the murine 4T1 breast cancer and B16F10 melanoma models to investigate morphological and molecular changes of the lymphatic network in tumor-draining LNs over time before the arrival of metastatic tumor cells. No LN metastasis was detected in either model until the last studied time points ([Figure S1](#mmc1){ref-type="supplementary-material"}). Tumor growth in both models was accompanied by an increased weight of the tumor-draining, but not the contralateral non-draining, inguinal LN, indicating a local tumor-mediated effect ([Figures 1](#fig1){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). In the 4T1 model, LN enlargement occurred already around day 4 after tumor cell injection, when tumors were barely palpable, and reached a plateau around day 10 ([Figure 1](#fig1){ref-type="fig"}A). In contrast, B16F10 tumor-draining LNs increased in weight more slowly and continued swelling until day 16, when mice had to be sacrificed ([Figure S2](#mmc1){ref-type="supplementary-material"}A).Figure 1Lymphatic Network Expansion in Tumor-Draining LNs Is Mediated by LEC Sprouting and Proliferation(A) 4T1 primary tumor growth and *ex vivo* inguinal LN weight.(B and C) Maximum intensity projections of 3D light-sheet-microscope images of whole LNs stained for the lymphatic marker LYVE-1 (B) at different times or (C) 10 days after 4T1 injection.(D) FACS quantification of LECs in naive and 4T1 tumor-draining LNs at day 10.(E and F) Immunofluorescence staining of 4T1 tumor-draining LNs for the lymphatic markers Prox1 and LYVE-1 and the proliferation marker Ki67.(E) Representative image of a tumor-draining LN with arrowheads indicating proliferating LECs.(F) Schematic of the analyzed LN areas (left) and quantification of LEC proliferation in these areas (right).Statistical significance was determined by (A) two-way ANOVA, (D) unpaired Student's t test, or (F) one-way ANOVA. Data are shown as mean with SD and differences were considered statistically significant when p \< 0.05, as indicated by ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001. See also [Videos S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"} and [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

3D light-sheet microscopy of whole LNs was used to assess 4T1 tumor-induced remodeling of the LN lymphatic network. A massive expansion of the lymphatic network started together with the enlargement of the LN around day 4 and progressed until day 20 ([Figure 1](#fig1){ref-type="fig"}B; [Videos S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). Higher magnification images revealed frequent filopodia formation by lymphatic vessels in tumor-draining LNs, which was not observed in naive LNs ([Figure 1](#fig1){ref-type="fig"}C). There were also clear alterations of the network architecture, with dilated lymphatic vessels and an expanded network as compared to naive LNs.

Video S1. Optical Sectioning Reveals the Lymphatic Network Architecture in Resting LNs of Naive Mice, Related to Figure 1Consecutive 3D light-sheet microscope images of a whole naive LN stained for the lymphatic marker LYVE-1.

Video S2. Optical Sectioning Reveals Altered Lymphatic Network Architecture in 4T1 Tumor-Draining LNs, Related to Figure 1Consecutive 3D light-sheet microscope images of a whole 4T1 tumor-draining LN stained for the lymphatic marker LYVE-1.

Fluorescence-activated cell sorting (FACS) analysis revealed an increased number of LECs in tumor-draining LNs in both tumor models, indicating that the enlargement of lymphatic vessels was at least partially mediated by LEC hyperplasia ([Figures 1](#fig1){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}B). Stainings of LN sections for LYVE-1, Prox1, and the proliferation marker Ki67 confirmed that the LEC proliferation rate was increased both in the subcapsular sinus and the medullary sinus of 4T1 tumor-draining, but not non-draining, LNs ([Figures 1](#fig1){ref-type="fig"}E, 1F, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D). Compared to a baseline LEC proliferation rate of less than 2% in resting LNs of naive mice, proliferation increased at day 4 after tumor cell injection and reached up to 10% in the subcapsular sinus and 6% in the medullary sinus around days 4--6. In accordance with previously published reports ([@bib35]), we observed that, besides LECs, other stromal cell populations, like blood vascular endothelial cells (BECs) and fibroblastic reticular cells (FRCs), as well as leukocytes expand significantly in tumor-draining LNs ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F).

In conclusion, these findings show that the enlargement of tumor-draining LNs is accompanied by a remarkable expansion of stromal cell populations and that the remodeling of the lymphatic network is mediated by lymphatic vessel sprouting and LEC proliferation.

RNA Sequencing Reveals a Distinct Expression Profile of LECs from Tumor-Draining LNs {#sec2.2}
------------------------------------------------------------------------------------

Given the major structural alterations of lymphatic vessels, we next sought to elucidate how LECs adapt to the environmental changes in tumor-draining LNs on a molecular level. We sorted LECs from 4T1 and B16F10 tumor-draining LNs and their respective naive controls and subjected them to RNA sequencing ([Figures 2](#fig2){ref-type="fig"}A, 2B, and [S3](#mmc1){ref-type="supplementary-material"}A--S3C; [Table S1](#mmc1){ref-type="supplementary-material"}). Robust expression of LEC-specific marker genes, but not of blood vessel- or leukocyte-specific markers, confirmed the high purity of the samples that were used for sequencing ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Principal-component analysis (PCA) showed that the samples clustered according to the four experimental groups ([Figure 2](#fig2){ref-type="fig"}C). Interestingly, PCA based on all genes resulted in a closer clustering according to the genetic background of the mice (BALB/c versus C57BL/6), whereas PCA based on differentially expressed genes suggested greater similarity by treatment (naive PBS versus tumor). Importantly, about one third of all differentially expressed genes were shared between both models ([Figure 2](#fig2){ref-type="fig"}D). These results indicate that LN LECs in different mouse strains have a distinct gene expression profile yet modify this expression in a similar fashion when subjected to tumor-derived stimuli, even if those are derived from very different tumor types (breast cancer and melanoma).Figure 2RNA Sequencing Reveals a Distinct Expression Profile of LECs from Tumor-Draining LNs(A) Schematic workflow for RNA sequencing of LN LECs.(B) Representative FACS plot showing the gating of LN LECs.(C) Principal-component analysis (PCA) of the sequenced LEC samples based on all genes (left) and differentially expressed genes (right).(D) Venn diagrams with the number of differentially expressed genes in LECs from tumor-draining LNs compared to naive in both tumor models.See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

In line with the morphological changes observed in the lymphatic sinuses of tumor-draining LNs ([Figure 1](#fig1){ref-type="fig"}C), gene set enrichment analysis showed that the differentially expressed genes in both tumor models were enriched for genes previously associated with sprouting tip cells ([@bib9], [@bib45]; [Figure S3](#mmc1){ref-type="supplementary-material"}E).

Clustering of universally deregulated genes in both models into functionally related groups based on gene ontology highlighted an upregulation of genes involved in cell division, immune-modulatory pathways, and cell adhesion, whereas many genes involved in transcription regulation and differentiation were downregulated ([Figures 3](#fig3){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A; [Table S2](#mmc1){ref-type="supplementary-material"}). Interestingly, we observed a considerable overlap with previously published gene expression datasets of LN LECs 6 days after viral infection ([@bib14]) and some overlap with gene expression datasets of LN LECs in ovalbumin-induced inflammation ([@bib25]; [Figure S4](#mmc1){ref-type="supplementary-material"}A), whereas no overlap with LEC migration-associated genes ([@bib51]) was found. For further studies, we focused on genes up- or downregulated in both tumor models that are involved in cell-cell interactions. Especially adhesion molecules play an important role in vascular biology because they orchestrate vessel formation, organization, stability, permeability, leukocyte transmigration, and metastasis. Genes related to cell-cell and cell-matrix adhesion were among the top differentially regulated hits in LECs of tumor-draining LNs ([Figures 3](#fig3){ref-type="fig"}A and 3B). For instance, expression of Jam3, the gene-encoding junctional adhesion molecule C (JAM-C), was significantly reduced in both tumor models ([Figures 3](#fig3){ref-type="fig"}B--3E). JAM-C is known to regulate vascular permeability, leukocyte transmigration, tumor cell interactions with endothelium, and metastasis ([@bib12], [@bib37], [@bib49]). We confirmed JAM-C downregulation on LECs of B16F10 tumor-draining compared to naive LNs ([Figure S4](#mmc1){ref-type="supplementary-material"}B), indicating that tumor-derived factors may alter the barrier function of LN LECs in this tumor model.Figure 3The Expression Pattern of Cell Adhesion Molecules Is Dramatically Changed in LECs from Tumor-Draining LNs(A) Heatmap of differentially expressed genes in tumor-draining compared to naive LN LECs. GO clusters of biological processes are indicated on the right.(B) Heatmap of differentially expressed cell adhesion genes (GO: 0007155) in both tumor models.(C--E) Differentially expressed genes displayed in (C) volcano plots, (D) violin plots, and (E) normalized read counts (fragments per kilobase of transcript per million mapped reads \[RPKM\]) in both tumor models compared to the respective naive controls.Data are shown as mean with SD and differences were considered statistically significant when p \< 0.05, as indicated by ^∗^p \< 0.05, and ^∗∗∗^p \< 0.001. See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.

In conclusion, these data highlight that LECs in tumor-draining LNs respond via transcriptional alteration of pathways that are key to their activity and function, predominantly regarding immune system regulation and cell adhesion.

Integrin αIIb Is Upregulated on LECs of Tumor-Draining LNs and Mediates Adhesion of LN LECs to Fibrinogen *In Vitro* {#sec2.3}
--------------------------------------------------------------------------------------------------------------------

Remarkably, RNA sequencing revealed high baseline expression of Itga2b in LN LECs, with a 2-fold increase in LECs of 4T1 tumor-draining LNs and an almost 3-fold increase in the B16F10 model ([Figures 3](#fig3){ref-type="fig"}B--3E). Itga2b codes for integrin αIIb, which is predominantly expressed by platelets, where it plays a crucial role in platelet aggregation and blood clotting. It pairs exclusively with integrin subunit β3 and binds to a variety of ligands, such as fibrinogen, fibronectin, vitronectin, and von Willebrand factor ([@bib23]). Recently, integrin αIIb was also shown to be expressed by a subset of LN LECs in mice and humans and to be upregulated in response to immunization ([@bib7]), but its function in LN LECs has not been clarified so far.

Immunofluorescence staining of LN sections revealed specific integrin αIIb staining in the lymphatic vascular network that was much stronger in tumor-draining LNs ([Figure 4](#fig4){ref-type="fig"}A). Quantification of integrin αIIb within the lymphatic area confirmed a significantly increased protein expression in LECs of both 4T1 and B16F10 tumor-draining LNs compared to their respective controls. FACS analysis of LN LECs showed a wide range of integrin αIIb expression over the whole LEC population ([Figure 4](#fig4){ref-type="fig"}B), confirming a previous report ([@bib7]) that integrin αIIb is only expressed by a subset of LN LECs. Although the integrin-αIIb-negative LEC subset barely expanded, the integrin-αIIb-positive population expanded massively in 4T1 tumor-draining LNs ([Figure 4](#fig4){ref-type="fig"}B). Further FACS analyses for integrin αIIb, KI67, and LYVE-1 indicated a trend toward increased proliferation of the integrin-αIIb-expressing LECs compared to integrin-αIIb-negative LECs, which however was not statistically significant ([Figure S4](#mmc1){ref-type="supplementary-material"}C). We also observed integrin αIIb staining in lymphatic sinuses in human-melanoma-draining LNs ([Figure 4](#fig4){ref-type="fig"}C).Figure 4Integrin αIIb Is Upregulated on LECs in Tumor-Draining LNs and Mediates Adhesion of LN LECs to Fibrinogen *In Vitro*(A) Representative images and quantification of integrin αIIb immunofluorescence stainings. Each dot represents one image; n = 8 LNs/group.(B) FACS analysis of integrin-αIIb-positive LECs in 4T1 tumor-draining LNs. n = 3 LNs/group.(C) Representative images of integrin αIIb expression in the subcapsular sinus of a human melanoma-draining LN.(D) FACS analysis of integrin αIIb expression on primary murine LN LECs *in vitro* after stimulation for 24 hr. Points represent biological replicates (n = 2--3).(E) FACS analysis of integrin αIIb expression by LN LECs *in vivo* in 4T1-bearing mice on day 10 after tumor implantation in response to VEGFR-3 and IFN-γ blockage. n = 3--4 mice/group.(F) Matrix adhesion assay of primary murine LN LECs under integrin αIIbβ3 blockage *in vitro*. Points represent biological replicates (n = 10).(G) LYVE-1/fibrinogen immunofluorescence stainings of naive and tumor-draining LNs.Statistical significance was determined by the unpaired Student's t test (A, B, D \[each group compared to the unstimulated control\] and F) and one-way ANOVA (E). Data are shown as mean with SD and differences were considered statistically significant when p \< 0.05, as indicated by ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To study potential integrin αIIb functions in LECs, we isolated primary LN LECs and subjected them to functional studies *in vitro*. Using FACS analysis, we found that these cells express low levels of integrin αIIb but upregulated it in response to IFN-γ or tumor-cell-conditioned medium (CM), but not to lymphotoxin α~2~/β~1~ ([Figure 4](#fig4){ref-type="fig"}D). Compellingly, although both 4T1 and B16F10 CM induced an upregulation of integrin αIIb protein expression in LN LECs, B16F10 CM had a stronger effect *in vitro*, similar to what was observed on the mRNA level in tumor-draining LNs *in vivo* ([Figures 3](#fig3){ref-type="fig"}C--3E and [4](#fig4){ref-type="fig"}D). In line with these *in vitro* results, systemic interferon (IFN)-γ blockage, but not blockade of VEGF receptor (VEGFR)-3, reduced the expression of integrin αIIb by LN LECs in 4T1-bearing mice *in vivo* ([Figure 4](#fig4){ref-type="fig"}E). Because the integrin αIIbβ3 complex in platelets strongly binds to fibrinogen, we investigated whether it might have similar ligand specificity in LN LECs. In a matrix adhesion assay, we tested the effect of integrin αIIbβ3 inhibition on binding of isolated LN LECs to fibrinogen, fibronectin, and collagen type I. Fibronectin and fibrinogen, but not collagen I, are known ligands for activated integrin αIIbβ3 on platelets. We found that blockade of integrin αIIbβ3 reduced LN LEC adhesion to fibrinogen, but not to collagen I or fibronectin ([Figure 4](#fig4){ref-type="fig"}F). Accordingly, we found a close association of LN LECs to fibrinogen and an increased presence of fibrinogen in tumor draining compared to naive LNs ([Figures 4](#fig4){ref-type="fig"}G and [S4](#mmc1){ref-type="supplementary-material"}D). In comparison, integrin αIIb expression and fibrinogen deposition around lymphatic vessels in primary tumors and control skin was heterogeneous and generally weaker ([Figure S4](#mmc1){ref-type="supplementary-material"}E). To further investigate the role of lymphatic integrin αIIb *in vivo*, we performed an antibody blockage experiment in 4T1-bearing mice. However, due to its effects on platelets, leading to disseminated bleeding, blockage could only be maintained for a limited time span after tumor inoculation (day 10). At this stage, no major effects on the number or proliferation rate of LN LECs were observed ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Taken together, these data demonstrate that tumor-associated LN LECs upregulate integrin αIIb in response to IFN-γ and suggest a role of integrin αIIb in lymphatic endothelial interaction with nodal fibrinogen.

Discussion {#sec3}
==========

LN swelling is common in the context of growing tumors, but the dynamics and mechanisms behind it have not been studied in detail so far. In this study, using 3D imaging of whole LNs *ex vivo*, we found that tumor-induced LN swelling is associated with a massive remodeling of the lymphatic vascular network, mediated by LEC sprouting and proliferation. These alterations are likely to be induced by lymphangiogenic factors that are drained from the primary tumor or produced by activated leukocytes, for example B cells ([@bib2], [@bib40]), in the tumor-draining LN because they were not detected in non-draining LNs, excluding systemic effects. Remarkably, remodeling started very early after tumor cell injection and no LN metastases were detected histologically at the studied time points, indicating that metastatic tumor cells are not involved in this process.

Lymphatic remodeling in advance of LN metastasis might represent the formation of a pre-metastatic, lymphovascular niche. Whereas factors such as the VEGFs, COX-2, or the heparin-binding factor midkine have been shown to mediate the formation of such niches ([@bib17], [@bib18], [@bib28], [@bib29]), the molecular profile of LECs that define them has not been described. In the present study, we performed complete RNA sequencing of LECs directly isolated from naive and tumor-draining LNs. Our data reveal that multiple cell adhesion molecules are differentially expressed in tumor-draining LN LECs. For instance, we observed downregulation of JAM-C on mRNA and protein levels in LN LECs of tumor-bearing mice. The role of JAM-C in endothelial cells is complex, and differential expression may have various consequences. High expression of JAM-C seems to increase permeability of endothelial barriers, transmigration of lymphocytes, and inflammatory leukocyte recruitment ([@bib49]). Importantly, expression of JAM-C binding partners, such as JAM-C itself, was found in many human tumor lines, among them, almost all melanoma and some breast cancer lines investigated in a recent report ([@bib21]). Although the direct consequences of JAM-C downregulation in tumor-draining LN LECs are difficult to estimate, previous findings suggest that lower JAM-C levels lead to decreased vessel permeability, decreased leukocyte trafficking in the LN, and possibly decreased interaction with metastasizing tumor cells ([@bib12], [@bib37], [@bib49]).

Interestingly, we found integrin αIIb (Itga2b) among the highest expressed and strongest upregulated genes in LN LECs and confirmed these findings on the protein level. The expression of integrin αIIb on a specific subset of LN LECs was discovered only recently, and its function in LECs has remained unknown ([@bib7]). We identify here that integrin αIIb mediates adhesion of LN LECs to fibrinogen *in vitro* and found co-localization of LECs with fibrinogen-rich LN areas *in vivo*. Although integrin αIIbβ3 can also bind to fibronectin, we did not observe an inhibition of LEC adhesion to fibronectin when integrin αIIbβ3 was blocked. Similarly, [@bib7] found that integrin αIIb expression is not required for LEC residence in fibronectin-rich LN areas *in vivo*. This is likely due to the expression of other fibronectin-binding molecules on LECs, such as β1 integrins ([@bib5]).

The extracellular matrix is greatly altered in tumor progression and plays a decisive role in lymphangiogenesis. Whereas fibrinogen is a plasma protein and usually not part of the extracellular matrix in healthy tissues, it can leak into wound areas and provide a provisional adhesive scaffold for the recruitment of cells ([@bib5]). Consequently, fibrinogen was also shown to be deposited in tumor-associated extracellular matrices ([@bib41]). Given the prominent remodeling of the LN architecture during tumor progression, fibrinogen deposition in tumor-draining LNs is not unlikely to occur. Indeed, we found that fibrinogen is greatly increased in tumor-draining LNs compared to control LNs and accumulated around lymphatic sinuses. This is in line with a recent report showing that fibrinogen is very abundant in afferent lymph and is efficiently retained by draining LNs ([@bib6]). Fibrinogen has been reported to promote hematogenous metastasis by shielding and protecting tumor cell emboli within the circulation ([@bib22]). Interestingly, expression or plasma levels of fibrinogen also correlate with LN metastasis in mouse cancer models and in cancer patients, respectively ([@bib1], [@bib30], [@bib31], [@bib48]), which indicates that fibrinogen deposition in draining LNs might contribute to the formation of pre-metastatic niches, potentially via lymphatic integrin αIIb. Furthermore, integrin αIIb might also bind to fibronectin and other ligands and may thereby provide outside-in signals that promote LN LEC migration and proliferation ([@bib11]). In conclusion, expression of integrin αIIb by LN LECs could play a role in lymphangiogenesis and lymphatic network remodeling in tumor-draining LNs. Of note, inhibition of integrins has been proposed before as a means to target tumor-induced lymphangiogenesis ([@bib5]). There are several integrin αIIbβ3 inhibitors (abciximab, eptifibatide, and tirofiban) that have been approved for preventative anti-thrombotic treatment to inhibit platelet aggregation and thrombus formation. However, treatment with these inhibitors might cause bleeding problems, especially in the context of leaky tumor blood vessels. Similarly, in our mouse models, inhibition of integrin αIIbβ3 using a F(ab)2 fragment could be maintained only for a short period of time, which did not suffice to detect major effects on lymphatic remodeling or subsequent metastasis. Thus, studying whether and how integrin αIIb might influence lymphatic network remodeling and tumor metastasis in tumor-draining LNs will require the generation of a lymphatic-specific knockout mouse model.

Taken together, in the present analysis, using tumor models of melanoma and breast cancer, we characterize the tumor-induced lymphatic network remodeling and describe the molecular adaptation of LECs in tumor-draining LNs. Interestingly, LECs in both tumor models show an overlapping regulation of gene expression, which suggests LN LECs might not only regulate lymphangiogenesis but also the adherence and survival of metastatic tumor cells. Together, these findings indicate that LN LECs are active players in shaping tumor progression and suggest that targeting of LN LECs or specific functions of them could represent a new way to therapeutically modulate tumor metastasis.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rat monoclonal anti-VEGFR3 clone mF4-31C1ImClone Systems / Eli LillyN/ARat monoclonal anti-IFN-γ clone R4-6A2BioXCellBE0054, RRID:[AB_1107692](nif-antibody:AB_1107692){#interref20}Rat control IgGSigma AldrichI4131, RRID:[AB_1163627](nif-antibody:AB_1163627){#interref25}Rat monoclonal anti-Itga2b clone Leo.H4EmfretM021-0Rat monoclonal anti-KLH clone LTF-2BioXCellBE0090, RRID:[AB_1107780](nif-antibody:AB_1107780){#interref30}Goat anti-Lyve-1R&DAF2125, RRID:[AB_2297188](nif-antibody:AB_2297188){#interref35}Rabbit anti-Lyve-1AngioBio11-034Rat monoclonal anti-Lyve-1 clone 4D17ReliaTech103-M130Goat anti-Prox1R&DAF2727, RRID:[AB_2170716](nif-antibody:AB_2170716){#interref40}Rat monoclonal anti-Ki67 clone TEC-3DakoM7249, RRID:[AB_2250503](nif-antibody:AB_2250503){#interref45}Rat monoclonal anti-CD41 clone MWReg30BD553847, RRID:[AB_395084](nif-antibody:AB_395084){#interref50}Rabbit anti-Jam-CProf. Beat Imhof, University of GenevaN/ARabbit anti-FibrinogenDakoA0080, RRID:[AB_578481](nif-antibody:AB_578481){#interref55}Rabbit anti-CytokeratinDakoZ0622, RRID:[AB_2650434](nif-antibody:AB_2650434){#interref60}Rabbit anti-GP100abcamab137078, RRID:[AB_2732921](nif-antibody:AB_2732921){#interref65}Goat anti-Lyve-1 BiotinR&DBAF2089, RRID:[AB_356247](nif-antibody:AB_356247){#interref70}Rabbit anti-CD41Sigma AldrichHPA031168, RRID:[AB_10664706](nif-antibody:AB_10664706){#interref75}Mouse monoclonal anti-CD45.2 FITC clone 104BD553772, RRID:[AB_395041](nif-antibody:AB_395041){#interref80}Rat monoclonal anti-CD45 APC-Cy7 clone 30-F11BioLegend103116, RRID:[AB_312981](nif-antibody:AB_312981){#interref85}Rat monoclonal anti-CD31 APC clone MEC13.3BD551262, RRID:[AB_398497](nif-antibody:AB_398497){#interref90}Hamster monoclonal anti-podoplanin PE clone 8.1.1eBioscience12-5381-80, RRID:[AB_1907440](nif-antibody:AB_1907440){#interref95}Rat monoclonal anti-CD41 BV421 clone MWReg30BioLegend133911, RRID:[AB_10960744](nif-antibody:AB_10960744){#interref100}Goat anti-GPNMBR&DAF2330, RRID:[AB_2112934](nif-antibody:AB_2112934){#interref105}Rat monoclonal anti-Ki67 eFluor450 clone SolA15eBioscience48-5698-82, RRID:[AB_11149124](nif-antibody:AB_11149124){#interref110}**Biological Samples**Human melanoma-draining lymph node sectionsThis paperN/A**Chemicals, Peptides, and Recombinant Proteins**Mouse IFN-γPeprotech315-05Mouse lymphotoxin α~2~/β~1~R&D1008-LY**Deposited Data**RNA sequencing dataThis paperENA: PRJEB22969**Experimental Models: Cell Lines**4T1-luc2Caliper Life Sciences124087, RRID:CVCL_L899B16F10ATCCCRL-6475, RRID:CVCL_0159**Experimental Models: Organisms/Strains**Balb/cByJRj wildtype miceJanvierN/AC57BL/6JRj wildtype miceJanvierN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael Detmar (<michael.detmar@pharma.ethz.ch>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

Female Balb/cByJRj (referred to as BALB/c) mice and C57BL/6JRj (referred to as C57BL/6) mice were purchased from Janvier and housed in an SOPF facility with free access to food and drinking water. Mice were used for tumor studies at an age of 10-12 weeks (BALB/c) or 8-10 weeks (C57BL/6). All experiments were approved by the Cantonal Veterinary Office Zurich (license numbers ZH011/12, ZH012/15, and ZH005/18).

### Cell lines {#sec4.3.2}

4T1 breast carcinoma cells expressing luc2 (Caliper Life Sciences) were cultured in DMEM supplemented with L-Glutamine and 10% FBS (all GIBCO). B16F10 cells (ATCC) were cultured in DMEM supplemented with GlutaMax, Pyruvate and 10% FBS (all GIBCO). All cell lines were maintained at 37°C in a humified incubator with 5% CO~2~, and were routinely tested for mycoplasma contamination (Mycoscope, Genlantis).

Method Details {#sec4.4}
--------------

### Tumor models {#sec4.4.1}

BALB/c mice were injected subcutaneously with 1x10^5^ 4T1 cells in 50 μl PBS (or PBS alone as control) into the 4th mammary fat pad and tumors were grown for 10 days (for RNA sequencing) or 20 days, unless indicated otherwise. C57BL/6 mice were injected intradermally with 1x10^5^ B16F10 cells (or PBS alone as control) into the flank and tumors were grown for 14 days, unless indicated otherwise.

In some experiments, mice were treated intraperitoneally on day 2, 5 and 8 after tumor inoculation with rat anti-mouse VEGFR3 (mF4-31C1, Imclone Systems Inc. / Eli Lilly, 800 μg / injection), rat anti-mouse IFN-γ (R4-6A2, BioXCell, 300 μg / injection) or control rat IgG (Sigma Aldrich, 800 μg / injection).

For integrin αIIb blocking experiments, F(ab)2 fragments were generated from a rat IgG2b control antibody (LTF-2, BioXCell) and an integrin αIIb blocking antibody (Leo.H4, EMFRET) using the Pierce F(ab)2 generation kit according to the manufacturer's instructions (Thermo Fisher). The resulting F(ab)2 fragments were sterile filtered and endotoxin-cleared using Pierce Detoxi-Gel columns (Thermo Fisher). Biologic activity was confirmed using a tail bleeding test (data not shown). 4T1 tumor-bearing mice were treated from day 4 to day 9 by intraperitoneal injection of 1 μg / g body weight of the F(ab)2 fragments and euthanized at day 10.

### 3D Light-sheet microscopy of LN whole mounts {#sec4.4.2}

Whole inguinal LNs were stained by immunofluorescence and optically cleared for light-sheet microscopy as previously described ([@bib15]). In brief, LNs (naive or tumor-draining) were fixed in 4% paraformaldehyde for 2 hours and permeabilized for 2 days using 0.5% Triton X-100 in PBS. The LNs were then incubated in blocking solution (1% bovine serum albumin (BSA), 0.1% Tween20, 0.03% NaN~3~ in PBS) for 2 days before the primary anti-LYVE-1 antibody (R&D AF2125 or AngioBio 11-034, 1:200) was added in blocking solution for 7 days at 4°C. Subsequently, LNs were washed, incubated for 7 days at 4°C with the secondary antibody (donkey anti-rabbit or anti-goat Alexa 488, Invitrogen, 1:200) in blocking solution, and washed again. For optical clearing of the tissue, LNs were embedded in 1% agarose (Ultrapure LMP Agarose, Invitrogen) in water. Following dehydration with a series of 50%, 70%, 95%, and 2x 100% methanol, the tissue was incubated in BABB (1:2 benzyl alcohol in benzyl benzoate, both Sigma Aldrich) for at least 2 days until optically cleared. 3D image stacks were taken with a light-sheet microscope (LaVision BioTech) with a 2x or a 6.3x objective and processed using Imaris (Bitplane) or Fiji (ImageJ, ([@bib38])) software.

### Immunofluorescence staining and analysis of frozen mouse LN sections {#sec4.4.3}

Inguinal LNs were embedded in OCT (Tissue-Tek) and frozen at −80°C. 7 μm thick tissue sections were fixed with acetone and 80% methanol, washed, and incubated with blocking solution (5% donkey serum, 1% BSA, 0.05% NaN~3~, 0.1% Triton X-100 in PBS) for 1 hour. Tissue sections were incubated with primary antibodies in blocking solution at 4°C overnight. Primary antibodies against LYVE-1 (AngioBio 11-034, 1:600 or R&D AF2125, 1:100 or ReliaTech 103-M130, 1:100), Prox-1 (R&D AF2727, 1:100), Ki67 (Dako M7249, 1:200), CD41/ integrin αIIb (BD 553847, 1:50), JAM-C (kindly provided by Prof. Beat Imhof, Université de Genève, 1:500), fibrinogen (Dako A0080, 1:100), pan-keratin/ wide spectrum Cytokeratin (Dako Z0622, 1:500), and melanoma gp100 (Abcam ab137078, 1:100) were used. After washing, sections were incubated with appropriate secondary antibodies (donkey anti-rabbit Alexa 350, donkey anti-rabbit, anti-goat or anti-rat Alexa 488, donkey anti-rabbit, anti-goat or anti-rat Alexa 594, donkey anti-rabbit Alexa 647; all Invitrogen, 1:200) for 30 min, washed, and mounted using Mowiol. Hoechst 33342 was used for nuclear staining. Images were acquired on a fluorescence microscope (Axioskop 2 mot plus) or an LSM 780 inverted confocal microscope (both Carl Zeiss).

Quantification of LEC proliferation was done using the Colocalization Analysis Plugin in ImageJ ([@bib39]). Data are shown as pooled data from 2 individual studies with a total of n = 8 mice per time point. Proliferation is expressed as percent of proliferating LECs (Ki67^+^) of total Prox1-positive LECs.

JAM-C and integrin αIIb staining was quantified with custom code written in MATLAB (MathWorks) and is shown as average pixel intensity over the LYVE-1 positive area per image. In brief, segmentation of the LYVE-1 positive area was done using the median filter to remove local noise and the Kittler thresholding algorithm. Average intensity of JAM-C and integrin αIIb staining within the obtained segmentation masks was measured in n = 8 individual LNs per condition.

### Immunofluorescence staining of human LNs {#sec4.4.4}

Tumor draining LNs from melanoma patients were collected at the Department of Dermatology, Tübingen, Germany. The presence of metastatic cells was determined by a board-certified pathologist. For stainings, formalin-fixed, paraffin-embedded tissue sections were deparaffinized and subjected to antigen retrieval in citrate buffer. Primary antibodies against LYVE-1 (biotinylated, R&D BAF2089, 1:50) and CD41/ integrin αIIb (Sigma HPA31168, 1:200) diluted in blocking solution were incubated over night at 4°C. After washing, slides were incubated with Streptavidin Alexa488 (1:200) and donkey anti-rabbit Alexa 594 (1:200) before mounting with Mowiol. Images were acquired on an LSM 780 inverted confocal microscope (Carl Zeiss).

### FACS sorting and analysis of LN LECs {#sec4.4.5}

For FACS sorting, 4T1 tumors were grown until day 10 and B16F10 tumors until day 14 before LN dissection. 4 naive inguinal LNs or 2 tumor-draining inguinal LNs were pooled per sample to obtain sufficient cell numbers. For each group, n = 7 (4T1 and BALB/c) or n = 8 (B16F10 and C57BL/6) samples were sorted. For FACS analysis, single LNs were stained and analyzed.

For sorting and analysis of LN stromal cells, LN suspensions were enriched for the stromal cell populations using a modified published technique ([@bib3]). In brief, LNs were dissected and the capsule was ruptured in cold basic medium (2%FCS, 1.2 mM CaCl~2~, in DMEM medium, GIBCO) using needles. After a pre-digestion in 1 mg/ml collagenase IV (GIBCO) and 40 μg/ml DNase I (Roche) in basic medium for 20 min at 37°C, the non-stromal cell supernatant was removed to enrich for LN stromal cells. The remaining LN fragments were digested with 3.5 mg/ml collagenase IV and 40 μg/ml DNase I in basic medium for 15 min at 37°C. Subsequently, LN fragments were mechanically disaggregated using an automated multichannel pipette (Eppendorf) and 5 mM EDTA was added to ensure maintenance of single cell suspension. Basic medium was added before the cell suspension was filtered through a 40 μm cell strainer (BD).

For tumor cell analysis, LNs and tumors were minced and digested with 4 mg/ml collagenase IV (GIBCO) and 40 μg/ml DNase I (Roche) in basic medium for 25 min at 37°C. LN samples were directly filtered through a 40 μm cell strainer (BD). Tumor samples were first filtered through a 70 μm cell strainer (BD), subjected to ACK lysis (Pharm Lyse, BD 555899), and also filtered through a 40 μm cell strainer (BD).

Cells were stained with fluorescent antibodies for 20 min on ice. Antibodies used were CD45.2 -- FITC (BD 553772, 1:100) or CD45 -- APC-Cy7 (BioLegend 103116, 1:400), CD31 -- APC (BD 551262, 1:200), podoplanin -- PE (8.1.1 eBioscience, 1:200), and CD41/integrin αIIb -- BV421 (BioLegend 133911, 1:100). GPNMB was stained with an unconjugated primary antibody (R&D AF2330, 1:100) in combination with an Alexa 488-conjugated secondary antibody (Invitrogen A-11055, 1:200). Intracellular staining for Ki67 -- eFluor450 (SOLA15 eBioscience, 1:200) was done using the Foxp3 intracellular staining kit (eBioscience) according to the instructions. After washing, cells were resuspended in FACS buffer (1% FBS, 2 mM EDTA in PBS) for sorting or acquisition. Live/dead staining was done either directly before acquisition (7-AAD, BioLegend) or together with the antibody incubation (Zombie NIR, BioLegend).

For RNA sequencing, LN LECs were sorted for high purity on a FACS Aria II (BD). Cells were sorted directly into RNA lysis buffer (RLT Plus, QIAGEN), vortexed, and immediately frozen at −80°C until RNA extraction. FACS acquisition was done on a LSRFortessa (BD).

### RNA extraction and sequencing of LN LECs {#sec4.4.6}

RNA was extracted and genomic DNA was eliminated from sorted LN LECs using the RNeasy Plus Micro kit (QIAGEN). RNA quantity and quality were assessed using a Bioanalyzer (Agilent). cDNA libraries were generated from high quality RNA samples using the Ovation Single Cell RNA-Seq System (NuGEN) and cDNA library quality was tested on a TapeStation (Agilent). RNA sequencing and differential expression analysis was performed by the Functional Genomics Center Zurich (FGCZ). For each group, n = 7 (4T1 and BALB/c) or n = 8 (B16F10 and C57BL/6) individual samples were sequenced using an Illumina Hiseq System. Sequencing depth was at least 3 mio read counts per sample. Differential gene expression analysis (individually for both tumor models and pooled for both) was done using DESeq2. Threshold for differential expression was defined as log2 fold change \> 0.5, p value \< 0.01. Principal component analysis (PCA), Venn diagrams ('VennDiagram' package), violin plots and gene expression heatmaps ('ggplot2′ package) were generated in R (v3.4.0). For heatmaps, gene expression was normalized and is shown as percent of maximum gene expression for each gene. The top 50 differentially expressed genes were furthermore compared to previously published gene expression datasets of LN LECs in pathological conditions. Gene expression data of LN LECs from day 6 after HSV infection ([@bib14]) were used as published. Gene expression of LN LECs during inflammation induced by ovalbumin injection into mice after adoptive transfer of OT-1 T cells ([@bib25]) was retrieved from GEO (GSE15907) and was re-analyzed using Geo2R. A log~2~FC of ± 1 and an FDR \< 0.05 was used to select differentially expressed genes. Gene set enrichment analysis (GSEA) comparing tumor-draining with naive LN LECs was performed on previously documented gene signatures of endothelial sprouting tip cells ([@bib9], [@bib45]) using GSEA software provided by the Broad Institute ([@bib46]). P values were estimated by 1000 permutations.

### Isolation, culture and stimulation of murine LN LECs {#sec4.4.7}

LN LECs were isolated as previously described ([@bib19]). In brief, LNs were digested with 0.25 mg/ml Liberase DH (Roche) and 200 U/ml DNase I (Sigma Aldrich) in RPMI medium (GIBCO) for 1 hour at 37°C. LN cell suspensions were filtered and plated in LN LEC medium (MEM alpha medium supplemented with 1x penicillin/streptomycin, 10% FBS, and 1x L-glutamine, all from GIBCO) on cell culture dishes pre-coated with 10 μg/ml fibronectin (Chemicon) and 10 μg/ml collagen (PureCol, Advanced BioMatrix). Cells were grown to confluency with regular exchange of the medium to remove non-adherent cells and enrich for LECs. Subsequently, cells were detached with Accutase (Biological Industries) and endothelial cells were positively selected with CD31^+^ microbeads (Miltenyi Biotech). LEC purity was checked by FACS analysis and LN LECs were cultured and used for *in vitro* assays up to passage 4 after isolation.

LECs were treated with 100 ng/ml murine interferon (IFN)-γ (Peprotech), 100 ng/ml murine lymphotoxin α~2~/β~1~ (LT, R&D), or with 4T1 or B16F10 tumor cell conditioned media (CM) for 24 hours before they were used for assays. For 4T1 and B16F10 CM, tumor cells were grown to 80% confluency, washed, and incubated in LN LEC medium for 24 hours. Conditioned medium was then collected, sterile filtered and stored at −20°C.

### Matrix adhesion assay of LN LECs {#sec4.4.8}

Isolated LN LECs were grown to near-confluency and incubated with IFN-γ for 24 hours to increase integrin αIIb expression. Subsequently, LECs were stained with 6 μM calcein (Invitrogen) in PBS for 10 min at 37°C. Cells were then washed with PBS and incubated with medium for 3 hours to remove excess dye, before they were detached by mild trypsinization. LECs were then incubated with 10 μg/ml integrin αIIbβ3 blocking antibody (Leo.H4, EMFRET) or control rat IgG (Sigma Aldrich I4131) in full medium for 30 min. 96-well-plates were coated with 10 μg/ml fibronectin (Chemicon), fibrinogen (abcam), or collagen (PureCol, Advanced BioMatrix) for 30 min at RT and subsequently blocked with 0.1% BSA/PBS for 30 min at 37°C before 1x10^4^ LECs/ well were added in media containing the integrin αIIbβ3 blocking antibody or the IgG control. Cells were allowed to adhere to the matrix for 1 hour at 37°C, then washed twice with PBS. Adherent cells were detected at 485 nm excitation and 538 nm emission wavelength using a fluorescence plate reader (SpectraMax, Molecular Devices).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical analysis was performed with GraphPad Prism 6.0 software using the unpaired Student's t test, one- or two-way ANOVA, as indicated in the figure legends. Data are shown as mean with standard deviation and differences were considered statistically significant when p \< 0.05, as indicated by asterisks with p \< 0.05 (^∗^), p \< 0.01 (^∗∗^) and p \< 0.001 (^∗∗∗^).

Data Availability {#sec4.6}
-----------------

The accession number for the RNA sequencing data reported in this paper is ENA: PRJEB22969.
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